BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 11691812)

  • 21. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
    Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M
    J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB; Brett S; Lechler RI
    Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
    He Y; Zhang J; Mi Z; Robbins P; Falo LD
    J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity.
    Brown M; Zhang Y; Dermine S; de Wynter EA; Hart C; Kitchener H; Stern PL; Skinner MA; Stacey SN
    Gene Ther; 2000 Oct; 7(19):1680-9. PubMed ID: 11083477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
    Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
    J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob.
    Matsui H; Sakurai F; Katayama K; Kurachi S; Tashiro K; Sugio K; Kawabata K; Mizuguchi H
    Virus Res; 2011 Jan; 155(1):48-54. PubMed ID: 20801174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity.
    Kim KW; Kim SH; Jang JH; Lee EY; Park SW; Um JH; Lee YJ; Lee CH; Yoon S; Seo SY; Jeong MH; Lee ST; Chung BS; Kang CD
    Cancer Immunol Immunother; 2004 Apr; 53(4):315-22. PubMed ID: 14685778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
    Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
    J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The induction of antigen-specific CTL by in situ Ad-REIC gene therapy.
    Ariyoshi Y; Watanabe M; Eikawa S; Yamazaki C; Sadahira T; Hirata T; Araki M; Ebara S; Nasu Y; Udono H; Kumon H
    Gene Ther; 2016 May; 23(5):408-14. PubMed ID: 26836118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.